^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Jeselhy (pimitespib) (HSP90 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TAS-116 plus nivolumab in patients with colorectal cancer and other solid tumors: an, open-label, dose-finding, and expansion phase Ib trial (EPOC1704)
Published date:
09/30/2021
Excerpt:
Objective tumor response was observed in 6 patients including 4 microsatellite stable (MSS) CRC, 1 microsatellite instability-high CRC and 1 leiomyosarcoma....TAS-116 160mg plus nivolumab had manageable safety profiles and anti-tumor activity especially for MSS CRC patients.
DOI:
10.1158/1078-0432.CCR-21-1929
Source:
Title:
TAS-116, an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: An open-label, dose-finding, and expansion phase Ib trial (EPOC1704).
Published date:
05/13/2020
Excerpt:
Objective tumor response was observed in 6 patients including 4 MSS CRC, 1 MSI-H CRC and 1 sarcoma, resulting in objective response rate (ORR) of 16% in MSS CRC without prior A-PD-1. PD-L1 CPS and TMB could be evaluated in 18 and 17 MSS CRC without prior A-PD-1, respectively. ORR was 27% in patients with CPS ≥1 and 0% in patients with CPS < 1. ORR was 33% with TMB-high (median as the cut-off) and 12% with TMB-low.
DOI:
10.1200/JCO.2020.38.15_suppl.4044
